These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 31666344)
1. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Bruna R; Benedetti F; Boccomini C; Patti C; Barbui AM; Pulsoni A; Musso M; Liberati AM; Gini G; Castellino C; Rossini F; Ciceri F; Rota-Scalabrini D; Stelitano C; Di Raimondo F; Tucci A; Devizzi L; Zoli V; Zallio F; Narni F; Dondi A; Parvis G; Semenzato G; Lanza F; Perrone T; Angrilli F; Billio A; Gueli A; Mantoan B; Rambaldi A; Gianni AM; Corradini P; Passera R; Ladetto M; Tarella C Haematologica; 2019 Nov; 104(11):2241-2248. PubMed ID: 31666344 [TBL] [Abstract][Full Text] [Related]
2. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Ladetto M; De Marco F; Benedetti F; Vitolo U; Patti C; Rambaldi A; Pulsoni A; Musso M; Liberati AM; Olivieri A; Gallamini A; Pogliani E; Rota Scalabrini D; Callea V; Di Raimondo F; Pavone V; Tucci A; Cortelazzo S; Levis A; Boccadoro M; Majolino I; Pileri A; Gianni AM; Passera R; Corradini P; Tarella C; ; Blood; 2008 Apr; 111(8):4004-13. PubMed ID: 18239086 [TBL] [Abstract][Full Text] [Related]
3. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Ladetto M; Vallet S; Benedetti F; Vitolo U; Martelli M; Callea V; Patti C; Coser P; Perrotti A; Sorio M; Boccomini C; Pulsoni A; Stelitano C; Scimè R; Boccadoro M; Rosato R; De Marco F; Zanni M; Corradini P; Tarella C Leukemia; 2006 Oct; 20(10):1840-7. PubMed ID: 16932351 [TBL] [Abstract][Full Text] [Related]
4. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K; Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034 [TBL] [Abstract][Full Text] [Related]
5. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539 [TBL] [Abstract][Full Text] [Related]
6. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772 [TBL] [Abstract][Full Text] [Related]
7. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554 [TBL] [Abstract][Full Text] [Related]
8. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650 [TBL] [Abstract][Full Text] [Related]
9. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Tarella C; Caracciolo D; Corradini P; Zallio F; Ladetto M; Cuttica A; Rossi G; Novero D; Gavarotti P; Pileri A Leukemia; 2000 Apr; 14(4):740-7. PubMed ID: 10764164 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G; Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. Bachy E; Brice P; Delarue R; Brousse N; Haioun C; Le Gouill S; Delmer A; Bordessoule D; Tilly H; Corront B; Allard C; Foussard C; Bosly A; Coiffier B; Gisselbrecht C; Solal-Celigny P; Salles G J Clin Oncol; 2010 Feb; 28(5):822-9. PubMed ID: 20026809 [TBL] [Abstract][Full Text] [Related]
14. Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. Rai S; Inoue H; Hanamoto H; Matsuda M; Maeda Y; Wada Y; Haeno T; Watatani Y; Kumode T; Hirase C; Espinoza JL; Morita Y; Tanaka H; Tatsumi Y; Matsumura I Int J Hematol; 2021 Aug; 114(2):205-216. PubMed ID: 33864623 [TBL] [Abstract][Full Text] [Related]
15. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Jäger U; Fridrik M; Zeitlinger M; Heintel D; Hopfinger G; Burgstaller S; Mannhalter C; Oberaigner W; Porpaczy E; Skrabs C; Einberger C; Drach J; Raderer M; Gaiger A; Putman M; Greil R; Haematologica; 2012 Sep; 97(9):1431-8. PubMed ID: 22511498 [TBL] [Abstract][Full Text] [Related]
16. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110 [TBL] [Abstract][Full Text] [Related]
17. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Avilés A; Delgado S; Fernández R; Talavera A; Neri N; Huerta-Guzmán J Eur J Haematol; 2002 Mar; 68(3):144-9. PubMed ID: 12068794 [TBL] [Abstract][Full Text] [Related]
18. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536 [TBL] [Abstract][Full Text] [Related]
19. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Zucca E; Rondeau S; Vanazzi A; Østenstad B; Mey UJM; Rauch D; Wahlin BE; Hitz F; Hernberg M; Johansson AS; de Nully Brown P; Hagberg H; Ferreri AJM; Lohri A; Novak U; Zander T; Bersvendsen H; Bargetzi M; Mingrone W; Krasniqi F; Dirnhofer S; Hayoz S; Hawle H; Vilei SB; Ghielmini M; Kimby E; Blood; 2019 Jul; 134(4):353-362. PubMed ID: 31101627 [TBL] [Abstract][Full Text] [Related]
20. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]